CD20 Antibody (10F381 (rituximab)) - Chimeric - Azide and BSA Free

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-52646

Recombinant Monoclonal Antibody.
Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Human, Cynomolgus Monkey, Rhesus Macaque

Applications

CyTOF-ready, Flow Cytometry

Label

Unconjugated

Antibody Source

Recombinant Monoclonal Rabbit IgG Kappa Clone # 10F381 (rituximab)

Format

Azide and BSA Free

Concentration

1 mg/ml

View all CD20 Antibodies »

Product Specifications

Immunogen

Human lymphoblastoid cell line SB.

Specificity

CD20 (Human B-lymphocyte-restricted differentiation antigen, Bp35), is a hydrophobic transmembrane protein with a molecular weight of approximately 35 kDa located on pre-B and mature B lymphocytes, and most B-cell non-Hodgkin's lymphomas, but is not found on stem cells, pro-B cells, normal plasma cells or other normal tissues .

Clonality

Monoclonal

Host

Rabbit

Isotype

IgG Kappa

Scientific Data Images for CD20 Antibody (10F381 (rituximab)) - Chimeric - Azide and BSA Free

Flow Cytometry: CD20 Antibody (10F381 (rituximab)) - Chimeric - Azide and BSA Free [NBP2-52646]

Flow Cytometry: CD20 Antibody (10F381 (rituximab)) - Chimeric - Azide and BSA Free [NBP2-52646]

Flow Cytometry: CD20 Antibody (10F381 (rituximab)) - Chimeric [NBP2-52646] - Flow-cytometry using the anti-CD20 research biosimilar antibody Rituximab. Cynomolgus monkey lymphocytes were stained with an isotype control (panel A) or the rabbit-chimeric version of Rituximab (NBP2-52646, panel B) at a concentration of 1 ug/ml for 30 mins at RT. After washing, bound antibody was detected using a AF488 conjugated donkey anti-rabbit antibody and cells analysed on a FACSCanto flow-cytometer.
Flow Cytometry: CD20 Antibody (10F381 (rituximab)) - Chimeric - Azide and BSA Free [NBP2-52646]

Flow Cytometry: CD20 Antibody (10F381 (rituximab)) - Chimeric - Azide and BSA Free [NBP2-52646]

Flow Cytometry: CD20 Antibody (10F381 (rituximab)) - Chimeric [NBP2-52646] - Flow-cytometry using the anti-CD20 research biosimilar antibody Rituximab. Human lymphocytes were stained with an isotype control (panel A) or the rabbit-chimeric version of Rituximab (NBP2-52646, panel B) at a concentration of 1 ug/ml for 30 mins at RT. After washing, bound antibody was detected using a AF488 conjugated donkey anti-rabbit antibody and cells analysed on a FACSCanto flow-cytometer.
Flow Cytometry: CD20 Antibody (10F381 (rituximab)) - Chimeric - Azide and BSA Free [NBP2-52646]

Flow Cytometry: CD20 Antibody (10F381 (rituximab)) - Chimeric - Azide and BSA Free [NBP2-52646]

Flow Cytometry: CD20 Antibody (10F381 (rituximab)) - Chimeric [NBP2-52646] - Flow-cytometry using the anti-CD20 research biosimilar antibody Rituximab. Rhesus monkey lymphocytes were stained with an isotype control (panel A) or the rabbit-chimeric version of Rituximab (NBP2-52646, panel B) at a concentration of 1 ug/ml for 30 mins at RT. After washing, bound antibody was detected using a AF488 conjugated donkey anti-rabbit antibody and cells analysed on a FACSCanto flow-cytometer.

Applications for CD20 Antibody (10F381 (rituximab)) - Chimeric - Azide and BSA Free

Application
Recommended Usage

Flow Cytometry

1:10 - 1:1000
Application Notes
This antibody is Cytof ready. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Formulation, Preparation, and Storage

Purification

Protein A purified

Formulation

PBS

Format

Azide and BSA Free

Preservative

0.02% Proclin 300

Concentration

1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C for up to 3 months. For longer storage, aliquot and store at -20C.

Background: CD20

CD20 is a non-glycosylated phosphoprotein that is expressed on the surface of normal and malignant B cells and functions in mediating calcium transport and B cell differentiation (1,2). CD20 is encoded by the membrane-spanning 4-domain family A member 1 (MS4A1) gene and, in humans, is located on chromosome 11q12 (1). The CD20 protein is 297 amino acids (aa) in length with a theoretical molecular weight (MW) of 33 kDa (1,2). Structurally, the CD20 protein has four membrane-spanning domains, two extracellular loop domains, and intracellular N- and C-terminal domains (1,2). CD20 is expressed at specific stages of B cell maturation including pre-B cells, mature naive and activated B cells, and memory B cells, but is absent from plasmablasts and plasma cells (1,3,4). Expression of CD20 is often increased on malignant B cells associated with various B cell disorders such as chronic lymphocytic leukemia (CLL), multiple sclerosis (MS), and rheumatoid arthritis (2-4). Anti-CD20 monoclonal antibody (mAb)-based therapies have become an appealing target for treating these immune-related disorders and cancers (1-5). Rituximab, a chimeric mAb, was the first FDA approved CD20 monoclonal antibody for the treatment of non-Hodgkin's lymphoma that is now commonly used to treat MS (2,3). Since its initial approval in 1997, several other chimeric and humanized anti-CD20 mAbs have been developed including Ofatumumab, Ublituximab, and Obinutuzumab (1-5). B cell depletion via CD20 mAbs can occur under different mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis (1-4). Many ongoing studies are focused on combination therapies with CD20 mAbs as an addition to chemotherapy, B cell receptor (BCR) signaling inhibitors, or BH3 mimetics (1,2,4). Additionally, the effects of bispecific antibodies and CD20 chimeric antigen receptor (CAR) T cell therapies are under investigation for the treatment of B cell malignancies (4,5).

References

1. Pavlasova G, Mraz M. The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy. Haematologica. 2020; 105(6):1494-1506. https://doi.org/10.3324/haematol.2019.243543

2. Payandeh Z, Bahrami AA, Hoseinpoor R, et al. The applications of anti-CD20 antibodies to treat various B cells disorders. Biomed Pharmacother. 2019; 109:2415-2426. https://doi.org/10.1016/j.biopha.2018.11.121

3. Margoni M, Preziosa P, Filippi M, Rocca MA. Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. J Neurol. 2022; 269(3):1316-1334. https://doi.org/10.1007/s00415-021-10744-x

4. Klein C, Jamois C, Nielsen T. Anti-CD20 treatment for B-cell malignancies: current status and future directions. Expert Opin Biol Ther. 2021; 21(2):161-181. https://doi.org/10.1080/14712598.2020.1822318

5. Sharman JP. Targeting CD20: teaching an old dog new tricks. Hematology Am Soc Hematol Educ Program. 2019; 2019(1):273-278. https://doi.org/10.1182/hematology.2019000031

Long Name

Cluster of Differentiation 20

Alternate Names

B1, Bp35, CD20, LEU-16, Ly-44, MS4A1, S7, biosimilar antibody, biosimilars

Gene Symbol

MS4A1

Additional CD20 Products

Product Documents for CD20 Antibody (10F381 (rituximab)) - Chimeric - Azide and BSA Free

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for CD20 Antibody (10F381 (rituximab)) - Chimeric - Azide and BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.